

Product Data Sheet

Taccalonolide A

Cat. No.: HY-N2416 CAS No.: 108885-68-3 Molecular Formula: $C_{36}H_{46}O_{14}$ Molecular Weight: 702.74

Target: Microtubule/Tubulin; Apoptosis

Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Apoptosis

Storage: 4°C, sealed storage, away from moisture and light

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

SOLVENT & SOLUBILITY

ln	٦	<i>l</i> ı	۰	r	n

DMSO: 100 mg/mL (142.30 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.4230 mL	7.1150 mL	14.2300 mL
	5 mM	0.2846 mL	1.4230 mL	2.8460 mL
	10 mM	0.1423 mL	0.7115 mL	1.4230 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.56 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.56 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.56 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Taccalonolide A is a microtubule stabilizer, which is a steroid isolated from Tacca chantrieri, with cytotoxic and antimalarial activities $^{[1][2]}$. Taccalonolide A causes G_2 -M accumulation, Bcl-2 phosphorylation and initiation of apoptosis $^{[1]}$. Taccalonolide A is effective in vitro against cell lines that overexpress P-glycoprotein (Pgp) and multidrug resistance protein 7 (MRP7), with an IC $_{50}$ of 622 nM for SK-OV-3 cells $^{[3]}$.
IC ₅₀ & Target	$microtubule^{[1]}$

Page 1 of 2 www.MedChemExpress.com

REFERENCES

- [1]. Tinley TL, et al. Taccalonolides E and A: Plant -derived steroids with microtubule-stabilizing activity. Cancer Res. 2003 Jun 15;63(12):3211-20.
- [2]. Risinger AL, et al. Taccalonolides: Novel microtubule stabilizers with clinical potential. Cancer Lett. 2010 May 1;291(1):14-9.
- [3]. Risinger AL, et al. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res. 2008 Nov 1;68(21):8881-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com